
HeartBeam, Inc. (NASDAQ:BEAT – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for HeartBeam in a note issued to investors on Monday, November 16th. HC Wainwright analyst Y. Chen now expects that the medical research company will earn ($0.30) per share for the year, up from their prior estimate of ($0.37). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for HeartBeam’s Q4 2026 earnings at ($0.06) EPS, Q1 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.22) EPS.
Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of HeartBeam to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings lowered shares of HeartBeam from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, HeartBeam presently has an average rating of “Moderate Buy” and an average target price of $4.00.
Read Our Latest Stock Report on HeartBeam
HeartBeam Price Performance
Shares of HeartBeam stock opened at $0.33 on Wednesday. HeartBeam has a 52-week low of $0.32 and a 52-week high of $4.00. The company’s fifty day moving average price is $0.43 and its two-hundred day moving average price is $0.79.
HeartBeam (NASDAQ:BEAT – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The medical research company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.08 million.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of BEAT. BlackRock Inc. acquired a new stake in shares of HeartBeam in the 2nd quarter valued at $741,000. Sigma Planning Corp grew its holdings in shares of HeartBeam by 86.9% in the 2nd quarter. Sigma Planning Corp now owns 247,700 shares of the medical research company’s stock worth $186,000 after purchasing an additional 115,150 shares during the last quarter. Beacon Pointe Advisors LLC acquired a new stake in shares of HeartBeam during the 2nd quarter worth about $185,000. Finally, Ritholtz Wealth Management acquired a new stake in shares of HeartBeam during the 3rd quarter worth about $103,000. 7.77% of the stock is currently owned by institutional investors and hedge funds.
About HeartBeam
HeartBeam, Inc. is a medical technology company developing portable cardiac monitoring tools. Its technology is designed to record electrical signals from the heart in three dimensions and use them to create a synthesized 12-lead electrocardiogram (ECG), which can provide clinicians with information about cardiac activity beyond that of a standard single-lead reading. The company’s HeartBeam System combines a compact, cable-free recording device with software for analyzing and presenting ECG data.
Featured Articles
- Five stocks we like better than HeartBeam
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
